局部应用Cp G寡聚脱氧核苷酸联合OX40单抗治疗肝细胞癌小鼠模型的效果分析

马士朝; 张超群; 孙殿兴

doi:10.3969/j.issn.1001-5256.2019.09.020

局部应用Cp G寡聚脱氧核苷酸联合OX40单抗治疗肝细胞癌小鼠模型的效果分析

DOI: 10.3969/j.issn.1001-5256.2019.09.020

1. 承德医学院
2. 解放军联勤保障部队第九八○医院全军肝病诊治中心

基金项目:

国家自然科学基金(30571667)；

详细信息

中图分类号: R735.7;R-332
计量
- 文章访问数: 285
- HTML全文浏览量: 22
- PDF下载量: 102
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-15
- 出版日期: 2019-09-20

Clinical effect of topical application of CpG oligodeoxynucleotide combined with OX40 monoclonal antibody for mouse model of hepatocellular carcinoma

Chengde Medical University
The Liver Disease Center of PLA, the 980th Hospital of PLA Joint Logistics Support Force

Research funding:

摘要

摘要: 目的探讨局部应用CpG寡聚脱氧核苷酸（CpG-ODN）联合OX40单抗方案对肝细胞癌的疗效,以及对远处同源肿瘤的治疗效果。方法在BALB/c雄性小鼠四肢腋窝皮下注射H22单细胞悬液,建立荷瘤模型,7 d后筛选出30只荷瘤体积相当的小鼠,随机分成模型对照组、CpG组、CpG+OX40组,每组10只,并在左下肢瘤内注射药物。选取10只同批正常小鼠作为正常对照组。计算荷瘤体积,ELISA法检测血清IL-12和IFNγ浓度,流式细胞术检测脾脏CD8+T淋巴细胞比例,比较3组小鼠治疗后的生存情况。计量资料多组间比较采用重复测量设计资料的方差分析和单因素方差分析,进一步两两组间比较采用LSD-t检验;采用log-rank检验分析3组小鼠（不包含正常组）生存率,并绘制生存曲线。结果给予治疗后,模型对照组荷瘤呈进行性增长,血清IL-12和IFNγ水平、脾脏CD8+T淋巴细胞比例较正常对照组均减低（P值均<0. 05）。与模型对照组相比,CpG组和CpG+OX40组干预荷瘤体积均缩小（P值均<0. 05）; CpG+OX40组远处荷瘤体积比CpG组和模型对照组增长减慢（P值均<0. 0...
- 癌,肝细胞 /
- OX40 /
- CpG寡聚脱氧核苷酸 /
- 免疫疗法 /
- 小鼠,近交BALB C /
- 动物实验
Abstract: Objective To investigate the clinical effect of topical application of CpG oligodeoxynucleotide ( CpG-ODN) combined with OX40 monoclonal antibody in the treatment of hepatocellular carcinoma and its therapeutic effect on distant homologous tumors. Methods H22 single cell suspension was subcutaneously injected into the axilla of the four limbs of BALB/c male mice to establish a tumor-bearing model. After seven days, 30 mice with a similar tumor volume were screened out and randomly divided into model control group, CpG group, and CpG + OX40 group, with 10 mice in each group, and drugs were injected into the tumor in the left lower limb. Ten normal mice in the same batch were selected as normal control group. Tumor volume was calculated, ELISA was used to measure the serum levels of interleukin-12 ( IL-12) and interferon-γ ( IFNγ) , and flow cytometry was used to measure the percentage of CD8+T lymphocytes in the spleen. The three groups were compared in terms of survival after treatment. Repeated measures analysis of variance and one-way analysis of variance were used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. The log-rank test was used to analyze survival rate for the model control group, CpG group, and CpG+ OX40 group, and survival curves were plotted. Results After treatment, the model control group had progressive growth of tumor, with significantly lower serum levels of IL-12 and IFNγ and percentage of spleen CD8+T lymphocytes than the normal control group ( all P <0. 05) . Compared with the model control group, the CpG group and the CpG + OX40 group had a significant reduction in tumor volume after intervention ( all P < 0. 05) . The CpG + OX40 group had a significantly lower growth rate of distant tumor than the CpG group and the model control group ( all P < 0. 05) , but there was no significant difference in distant tumor volume between the CpG group and the model control group ( P > 0. 05) . Compared with the model control group, the CpG group and the CpG + OX40 group had significant increases in serum levels of IL-12 and IFN-γ and percentage of spleen CD8+T lymphocytes ( all P < 0. 05) , which were significantly higher in the CpG +OX40 group than in the CpG group ( all P < 0. 05) . The CpG + OX40 group had a significantly higher survival rate than the model control group and the CpG group ( both P < 0. 05) , while there was no significant difference between the CpG group and the model control group ( P> 0. 05) . Conclusion OX40 monoclonal antibody combined with CpG-ODN can reduce liver tumor volume, effectively slow down the growth of distant tumors, and prolong the survival time of mice.
- carcinoma, hepatocellular /
- OX40 /
- CpG oligodeoxynucleotide /
- immunotherapy /
- mice, inbred BALB C /
- animal experimentation

HTML全文

参考文献(21)

[1] GRANDHI MS, KIM A, RONNEKLEIVKELLY SM, et al. Hepatocellular carcinoma:From diagnosis to treatment[J]. Surg Oncol, 2016, 25 (2) :74-85.

[2] LIANG S, HU J, XIE Y, et al. A polyethylenimine-modified carboxyl-poly (styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-βreceptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice[J]. Int J Nanomedicine, 2016, 11:6753-6762.

[3] JIA H, ZHAO T, ZOU D, et al. Therapeutic injection of a CType CpG ODN induced an antitumor immune response in C57/BL6 mice of orthotopically transplanted hepatocellular carcinoma[J]. Oncol Res, 2016, 23 (6) :321-326.

[4] ASPESLAGH S, POSTELVINAY S, RUSAKIEWICZ S, et al.Rationale for anti-OX40 cancer immunotherapy[J]. Eur J Cancer, 2016, 52:50-66.

[5] VIRANI N, THAVATHIRU E, MCKERNAN P, et al. Anti-CD73and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer[J]. Cancer Lett, 2018, 425:174-182.

[6] ITO S, SHIROTA H, KASAHARA Y, et al. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model[J]. Cancer Immunol Immunother, 2017, 66 (11) :1485-1496.

[7] VOO KS, FOGLIETTA M, PERCIVALLE E, et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T cell function in follicular lymphoma[J]. Int J Cancer, 2014, 135 (12) :2834-2846.

[8] TU T, BUDZINSKA MA, MACZUREK AE, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development[J]. Int J Mol Sci, 2014, 15 (6) :9422-9458.

[9] DING J, WU J. Epigenetic regulation of hepatic tumor-initiating cells[J]. Front Biosci, 2015, 20 (6) :946-963.

[10] GARRIS C, ARLAUCKAS SP, KOHLER RH, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γand IL-12[J].Immunity, 2018, 49 (6) :1148-1161.

[11] SHEN K, CUI J, WEI Y, et al. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer:A meta-analysis[J]. J Thorac Dis, 2018, 10 (12) :6636-6652.

[12] SIU EH, CHAN AWH, CHONG CC, et al. Treatment of advanced hepatocellular carcinoma:Immunotherapy from checkpoint blockade to potential of cellular treatment[J].Transl Gastroenterol Hepatol, 2018, 3:89.

[13] FINKELMEIER F, WAIDMANN O, TROJAN J. Nivolumab for the treatment of hepatocellular carcinoma[J]. Expert Rev Anticancer Ther, 2018, 18 (12) :1169-1175.

[14] NADEAU BA, FECHER LA, OWENS SR, et al. Liver toxicity with cancer checkpoint inhibitor therapy[J]. Semin Liver Dis, 2018, 38 (4) :366-378.

[15] SAGIVBARFI I, CZERWINSKI DK, LEVY S, et al. Eradication of spontaneous malignancy by local immunotherapy[J]. Sci Transl Med, 2018, 10 (426) :eaan4488.

[16] NOURI N, GARBE C. Intralesional immunotherapy as a strategy to treat melanoma[J]. Expert Opin Biol Ther, 2016, 16 (5) :619-626.

[17] GUPTA V, KALIA N, YADAV M, et al. Optimization and qualification of the single molecule array digital immunoassay for IL-12p70 in plasma of cancer patients[J]. Bioanalysis, 2018, 10 (17) :1413-1425.

[18] DILLINGER B, AHMADIERBER S, LAU M, et al. IFN-γand tumor gangliosides:Implications for the tumor microenvironment[J]. Cell Immunol, 2018, 325:33-40.

[19] WALLIN RPA, SUNDQUIST VS, BRAKENHIELM E, et al. Angiostatic effects of NK cell-derived IFN-γcounteracted by tumour cell Bcl-xL expression[J]. Scand J Immunol, 2014, 79 (2) :90-97.

[20] SFONDRINI L, SOMMARIVA M, TORTORETO M, et al. Antitumor activity of CpG-ODN aerosol in mouse lung metastases[J]. Int J Cancer, 2013, 133 (2) :383-393.

[21] BUCHAN SL, ROGEL A, ALSHAMKHANI A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy[J]. Blood, 2017, 131 (1) :39-48.

施引文献

资源附件(0)

访问统计